Residual corticosteroid production in autoimmune addison´s disease
1University of Bergen, Department of Clinical Science, Bergen, Norway; 2University of Bergen, KG Jebsen center for Autoimmune Disorders, Bergen, Norway; 3Karolinska Institutet, Department of Molecular Medicine and Surgery, Sweden; 4Örebro University Hospital, Department of Medicine, Örebro, Sweden;5Haukeland University Hospital, Department of Medicine, Bergen, Norway; 6Endocrinology in Charlottenburg, Berlin, Germany; 7Oslo University Hospital, Department of Endocrinology, Oslo, Norway; 8Karolinska University Hospital, Department of Endocrinology, Metabolism and Diabetes, Stockholm, Sweden; 9Vestfold Hospital Trust, Department of Medicine, Tønsberg, Norway; 10Haugesund Hospital, Department of Internal Medicine, Haugesund, Norway; 11Stavanger University Hospital, Department of Endocrinology, Stavanger, Norway; 12Sørlandet Hospital, Kristiansand, Department of Medicine, Kristiansand, Norway; 13Drammen Hospital, Vestre Viken Health Trust, Department of Medicine, Drammen, Norway; 14Akershus University Hospital, Department of Endocrinology, Lørenskog, Norway; 15Umeå University, Department of Public Health and Clinical Medicine, Umeå, Sweden; 16University Hospital of North Norway, Division of Internal Medicine, Tromsø, Norway; 17Tromsø Endocrine Research Group, UiT the Arctic University of Norway, Department of Clinical Medicine, Tromsø, Norway; 18Innlandet Hospital Trust, Section of Endocrinology, Hamar, Norway; 19Linköping University, Department of Endocrinology and Department of Health, Medicine and Caring Sciences, Linköping, Sweden; 20Sørlandet Hospital, Arendal, Department of Medicine, Arendal, Norway; 21Karolinska Institutet, Department of Medicine (Solna), Karolinska University Hospital, Stockholm, Sweden
ea0070aep1